The treatment, called Ofev, slows the rate of decline in pulmonary function in adults with the rare lung condition.The FDA granted approval of Ofev to treat the disease to Boehringer Ingelheim.
Ofev was originally approved in 2014 for adult patients with idiopathic pulmonary fibrosis.
Read the full report here.
More articles on pharmacy:
Civica Rx says it isn’t afraid of competition
Cigna rolls out plan to fully cover expensive gene therapies
Rutgers to close 3 on-campus pharmacies
